Physician profile
Robert E Carroll
NPI 1457465262
$41,978.75
in general payments reported to CMS, 2019-2025
9 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $6,153 · 2021: $1,216 · 2022: $19K · 2023: $15K · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Travel and Lodging: $2,370 · Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,066.00 |
| Travel and Lodging | $2,370.37 |
| Food and Beverage | $715.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $41,283.13 | 2020-2025 | Gattex |
| Mauna Kea Technologies, INC. | $226.31 | 2019-2023 | |
| Digestive Care, INC. | $225.63 | 2019 | |
| Ironwood Pharmaceuticals, INC | $167.33 | 2025 | |
| Janssen Pharmaceuticals, INC | $33.90 | 2022 | |
| Olympus America INC. | $30.33 | 2019 | |
| Avanos Medical | $12.12 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.